Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Assessment of acute bone loading in humans using [18F]NaF PET/MRI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bone turnover markers in children and adolescents with type 1 diabetes-A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Eva W Iepsen
  • Jinyi Zhang
  • Mette Hollensted
  • Sten Madsbad
  • Torben Hansen
  • Jens J Holst
  • Niklas R Jørgensen
  • Jens-Christian Holm
  • Signe S Torekov
Vis graf over relationer

Pathogenic mutations in the melanocortin-4 receptor (MC4R) are associated with obesity, increased linear growth, and higher bone mass in children, and rodent studies have indicated an effect of the MC4R on bone turnover. Furthermore, GLP-1 receptor agonists (GLP-1 RAs) may influence bone metabolism. However, these associations have not been assessed in adults with pathogenic MC4R mutations. Thus, we wished to assess the impact of the MC4R on bone mass and metabolism. Secondly, we wished to investigate the impact of the GLP-1 RA liraglutide on bone mass in adults with pathogenic MC4R mutations. 17 patients with obesity-causing MC4R mutations (BMI: 35.5 ± 7.6) and 35 matched control participants with common obesity (BMI: 34.3 ± 7.1) underwent a DEXA scan for assessment of bone mineral density (BMD), bone mineral apparent density [BMAD = (BMD/√(bone area)], and bone turnover markers (BTMs). Individuals with a BMI above 28 (14 MC4R mutation carriers and 28 matched control participants) underwent 16 weeks treatment with liraglutide 3.0 mg. The MC4R group had higher BMD [mean difference: 0.065 g/m2 (- 0.008 to 0.138), p = 0.03], but BMAD and BTMS were not different compared to the control group. In response to liraglutide, BMAD increased in the control group, compared to no change in the MC4R group [mean group difference: 0.0007 (0.0001-0.001), p = 0.04]. In conclusion, BMD is increased in MC4R causal obesity compared to common obesity, but when corrected for body size (BMAD), bone mass was not increased, and no evidence of an influence of the MC4R on bone metabolism in adults was found. Liraglutide treatment did not change bone metabolism in MC4R causal obesity, but increased bone mass as measured by BMAD in common obesity.

OriginalsprogEngelsk
TidsskriftJournal of Bone and Mineral Metabolism
ISSN0914-8779
DOI
StatusE-pub ahead of print - 30 aug. 2019

ID: 57876896